http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 07:02:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Relmada+appoints+Michael+Quirk+as+senior+advisor+for+sepranolone+program/26632490.html <p>Relmada Therapeutics Inc. (NASDAQ: RLMD) appointed Michael Quirk as Senior Advisor for its sepranolone program. Quirk brings over 20 years of neuroscience drug discovery and development experience, including his previous role as Chief Scientific Officer at Sage Therapeutics.</p><p>Sepranolone is a GABAA receptor modulator being developed to treat Prader-Willi Syndrome and other central nervous system disorders. The drug selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling.</p><p>"His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology," said http://www.streetinsider.com/Corporate+News/Relmada+appoints+Michael+Quirk+as+senior+advisor+for+sepranolone+program/26632490.html Thu, 11 Jun 2026 07:02:13 -0400 RLMD http://www.streetinsider.com/Management+Changes/Relmada+appoints+Michael+Quirk+as+senior+advisor+for+sepranolone+program/26632490.html <p>Relmada Therapeutics Inc. (NASDAQ: RLMD) appointed Michael Quirk as Senior Advisor for its sepranolone program. Quirk brings over 20 years of neuroscience drug discovery and development experience, including his previous role as Chief Scientific Officer at Sage Therapeutics.</p><p>Sepranolone is a GABAA receptor modulator being developed to treat Prader-Willi Syndrome and other central nervous system disorders. The drug selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling.</p><p>"His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology," said http://www.streetinsider.com/Management+Changes/Relmada+appoints+Michael+Quirk+as+senior+advisor+for+sepranolone+program/26632490.html Thu, 11 Jun 2026 07:02:13 -0400 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html <ul type="disc"><li style="margin-bottom:6pt;"><em>Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.</em><br/><br/></li></ul> <p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4YkM_GVSw8EYb8XOyZOL_Q2qp5nH3jK8ktxKGBAABAursdBId-2rOAwJyjUXX9koaunyiwKXnzINPdniALDW7OeAyqa2k=" rel="nofollow" target="_blank">Relmada Therapeutics, Inc.</a></strong> (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+Appoints+CNS+Drug+Development+Veteran+Michael+Quirk+as+Senior+Advisor+for+Sepranolone+Program/26632411.html Thu, 11 Jun 2026 07:00:00 -0400 A.03350906 A.50113795 O.01868273 O.11364802 O.22050275 RLMD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++RELMADA+THERAPEUTICS%2C++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26625231.html si-local-file:///var/storage/secattach/20260609/26625231.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++RELMADA+THERAPEUTICS%2C++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26625231.html Tue, 09 Jun 2026 20:04:00 -0400 O.22050275 RLMD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++RELMADA+THERAPEUTICS%2C++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26625231.html si-local-file:///var/storage/secattach/20260609/26625231.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++RELMADA+THERAPEUTICS%2C++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26625231.html Tue, 09 Jun 2026 20:04:00 -0400 O.22050275 RLMD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RELMADA+THERAPEUTICS%2C+++++For%3A+May+27/26568670.html si-local-file:///var/storage/secattach/20260528/26568670.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RELMADA+THERAPEUTICS%2C+++++For%3A+May+27/26568670.html Thu, 28 May 2026 17:00:00 -0400 O.22050275 RLMD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RELMADA+THERAPEUTICS%2C+++++For%3A+May+27/26568670.html si-local-file:///var/storage/secattach/20260528/26568670.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RELMADA+THERAPEUTICS%2C+++++For%3A+May+27/26568670.html Thu, 28 May 2026 17:00:00 -0400 O.22050275 RLMD http://www.streetinsider.com/General+News/Relmada+Therapeutics+%28RLMD%29+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26561024.html <p>Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p><p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br />Format: Fireside Chat<br />Date: Thursday, June 4, 2026<br />Time: 12:50 PM ET<br />Webcast: <span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow">Click Here</span></p><p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a http://www.streetinsider.com/General+News/Relmada+Therapeutics+%28RLMD%29+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26561024.html Thu, 28 May 2026 07:04:10 -0400 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Press+Releases/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html <p align="justify" style="padding-left:0pt;">CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.</p> <p style="padding-left:0pt;"><strong>Jefferies Global Healthcare Conference Details</strong><br/>Format: Fireside Chat<br/>Date: Thursday, June 4, 2026<br/>Time: 12:50 PM ET<br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nXpXPMsaPkUzvzJZuanOlM_KF0nZFgQWvTlcmNR_9KFDMPtFZgu73sjcAQmqXyPJHSayFGOWH644BZMZU2tDQgQjNAosN6ULCOX3V-nTRqhpyxstNNsdj6sUSdCXr4nNjysvQE8EXfvIIJBvtnNGwyQrAgB6pkY2SDAy4QV5f0=" rel="nofollow" target="_blank">Click Here</a></p> <p align="justify" style="padding-left:0pt;">Management will also be available for one-on-one http://www.streetinsider.com/Globe+Newswire/Relmada+Therapeutics+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26560988.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 O.22050275 O.54516537 RLMD